FDA approves first ever China-made biologic for use in U.S. trials
By Cornelia Zou
Wednesday, May 7, 2014
HONG KONG The U.S. FDA has, for the first time ever, approved the use of a biologic product made by a Chinese company in U.S. investigational new drug trials. R&D services giant Wuxi Pharmatech Inc. (NYSE:WX) got the green light for HIV therapy drug ibalizumab (TMB-355), which it is manufacturing for Taiwan Taimed Biologics Inc., of Taipei, Taiwan.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.